RELEUKO

Peak

filgrastim

BLASUBCUTANEOUSSOLUTION
Approved
Feb 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Pharmacologic Class:

Leukocyte Growth Factor

Clinical Trials (5)

NCT07416955Phase 1Completed

Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults

Started Apr 2025
180 enrolled
Healthy Volunteer
NCT05796570Phase 2Recruiting

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

Started Apr 2023
NCT05130827Phase 2Active Not Recruiting

Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)

Started Dec 2021
NCT03294577Phase 3Unknown

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

Started Oct 2019
NCT03571633Phase 2Active Not Recruiting

Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer

Started Aug 2018
90 enrolled
HER2-positive Breast CancerOperable Breast Cancer